The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

Publication | Closed Access

DOI

Citations

References

2005

Year

Robert P. Giugliano, L. Kristin Newby, Robert A. Harrington, C. Michael Gibson, Frans Van de Werf, Paul W. Armstrong, Gilles Montalescot, James C. Gilbert, John Strony, Robert M. Califf,

American Heart Journal

ThrombosisCardiovascular DiseaseCoronary Artery DiseaseClinical TrialsClinical BenefitsPharmacotherapyAcute Myocardial InfarctionMedicineEarly AcsCardiologyEmergency MedicineEarly Front-loaded EptifibatideMyocardial Infarction